Targeting prostate cancer with the anti-PSMA scFvD2B: a theranostic promise for nuclear medicine

ConclusionscFvD2B seems to be a promising fragment as a molecular vector in NM applications. Nevertheless, further investigations, especially with radiometal-labeled scFvD2B, are necessary to better characterize and optimize the unique properties of this fragment, providing the basis for a rapid translation into the clinic.

Source: Clinical and Translational Imaging - July 30, 2019 Category: Radiology Source Type: research